TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that an application for …
U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab
TOKYO, Jul 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration …